| Heart Failure (HF) |
1 |
1 |
| Cardiovascular Imaging |
0 |
0.9 |
| Clinical Guidelines |
0 |
0.99 |
| Ejection Fraction |
0 |
0.61 |
| Arrhythmia |
0 |
0.48 |
| Hypertension |
0 |
0.95 |
| Cardiomyopathy |
0 |
0.4 |
| Atrial Fibrillation |
0 |
0.39 |
| SGLT2 Inhibitor |
0 |
0.38 |
| ACE Inhibitor |
0 |
0.36 |
| Heart |
0 |
0.35 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.35 |
| Type 2 Diabetes Mellitus |
0 |
0.35 |
| Atrioventricular Block |
0 |
0.28 |
| Atrioventricular Block First Degree |
0 |
0.25 |
| Atrioventricular Block Third Degree |
0 |
0.25 |
| Cardiac Resynchronization Therapy |
0 |
0.18 |
| Angiotensin II Receptor Blockade |
0 |
0.15 |
| Europe |
0 |
0.15 |
| Receptors |
0 |
0.15 |
| Beta Blockers |
0 |
0.09 |
| Revenue and Practice Management |
0 |
0.09 |
| Electrophysiology |
0 |
0.07 |
| Hospital |
0 |
0.06 |
| Implantable Cardioverter-Defibrillator |
0 |
0.04 |
| Otolaryngology |
0 |
0.04 |
| Blood |
0 |
0.03 |
| Defibrillator |
0 |
0.03 |
| Diuretics |
0 |
0.03 |
| Food and Drug Administration (FDA) |
0 |
0.03 |
| Salary and Compensation |
0 |
0.03 |
| Sinus |
0 |
0.03 |
| Transplant Evaluation |
0 |
0.03 |